{"id":484630,"date":"2021-04-29T16:05:06","date_gmt":"2021-04-29T20:05:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/"},"modified":"2021-04-29T16:05:06","modified_gmt":"2021-04-29T20:05:06","slug":"spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/","title":{"rendered":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., April  29, 2021  (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.<\/p>\n<p align=\"justify\">To access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122. The audio webcast can be accessed under \u201cEvents and Presentations\u201d in the Investor and Media section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YLXVOEuJrm3yEqj5IQNw_Qkz6XXE78HKLnFs_zl4LMYVtcptmfSbEG1qM9d6XH8HSEe9IdueUpUdVsHB-qdJnTIqopvCKD3cMxLYqMdmq1s=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em>www.sperotherapeutics.com<\/em><\/strong><\/a>. The archived webcast will also be available on Spero\u2019s website for 30 days following the call.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Spero<\/strong>\u00a0<strong>Therapeutics<\/strong><br \/>Spero Therapeutics, Inc.\u00a0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.<\/p>\n<p align=\"justify\">Spero\u2019s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In\u00a0September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.<\/p>\n<p align=\"justify\">Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.<\/p>\n<p align=\"justify\">Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.<\/p>\n<p align=\"justify\">For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JulPgfb-WtFN1JBZ9Gxoe2ZgiAEZDm_bW5MfHSd82tz16vLn_c6oRJ2YorAJYW7Z7fNwKoC_o-jcQ8hS1JquAPep-bNXenHSH3Lgo7TPHfM=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em>https:\/\/sperotherapeutics.com<\/em><\/strong><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashley Robinson<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H_4uPWErb7mDGc3OFIisA3uuywhKqNRyc5ZtbFJ8GNHBG-3XsNM6hdtDwqKzXTDpTK5fi1sK2sZH3fVGUUcfVZP6ExcUxsvZri14XEbkvYA=\" rel=\"nofollow noopener\" target=\"_blank\">arr@lifesciadvisors.com<\/a><br \/>617-430-7577<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Vf4CLeSUAwSKugLWmiTOuUEF0bu7hAdISEgDc8Cg6s96fEcVyxIiFWI37k6wgxA8D5EtDEBiv8z_9BOD4jvkU_ObYzEZ1xyPa_vU0pDevB7nKovivD6rc7LvDCDRzNk\" rel=\"nofollow noopener\" target=\"_blank\">media@sperotherapeutics.com<\/a>\n      <\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/972ffd2f-a53e-43d3-8763-103bb98bcfe5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline. To access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122. The audio webcast can be accessed under \u201cEvents and Presentations\u201d in the Investor and Media section of the Company\u2019s website at\u00a0www.sperotherapeutics.com. The archived webcast will also be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484630","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline. To access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122. The audio webcast can be accessed under \u201cEvents and Presentations\u201d in the Investor and Media section of the Company\u2019s website at\u00a0www.sperotherapeutics.com. The archived webcast will also be available &hellip; Continue reading &quot;Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T20:05:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021\",\"datePublished\":\"2021-04-29T20:05:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/\"},\"wordCount\":304,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/\",\"name\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\",\"datePublished\":\"2021-04-29T20:05:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline. To access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122. The audio webcast can be accessed under \u201cEvents and Presentations\u201d in the Investor and Media section of the Company\u2019s website at\u00a0www.sperotherapeutics.com. The archived webcast will also be available &hellip; Continue reading \"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T20:05:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021","datePublished":"2021-04-29T20:05:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/"},"wordCount":304,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/","name":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=","datePublished":"2021-04-29T20:05:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNjAzNSM0MTQ1NDAzIzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-provide-business-update-and-report-first-quarter-2021-financial-results-on-thursday-may-6-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484630"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484630\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}